Alliance signs new agreement for Diclectin in key European countries

13 September 2016

The UK’s Alliance Pharma (AIM: APH) has signed a further licensing and distribution agreement with Duchesnay of Canada for Diclectin (doxylamine succinate – pyridoxine) delayed-release tablets), a proven product to treat nausea and vomiting of pregnancy.

Alliance acquired UK rights to Diclectin in January 2015 and this additional agreement secures rights to launch the product in a further nine European Union countries including Germany, France and Italy.

This is Alliance's first significant distribution agreement since acquiring the Sinclair Healthcare Products business in December 2015, which substantially increased Alliance's European footprint, the company noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK